EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical …

W Zhang, M Doherty, N Arden, B Bannwarth… - Annals of the …, 2005 - ard.bmj.com
Objective: To develop evidence based recommendations for the management of hip
osteoarthritis (OA). Methods: The multidisciplinary guideline development group comprised …

Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients

A Rostom, L Goldkind, L Laine - Clinical Gastroenterology and Hepatology, 2005 - Elsevier
Background & Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) might cause hepatic
side effects, but the frequency of these laboratory and clinical side effects is uncertain …

Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty

E Losina, AD Paltiel, AM Weinstein… - Arthritis care & …, 2015 - Wiley Online Library
Objective The impact of increasing utilization of total knee arthroplasty (TKA) on lifetime
costs in persons with knee osteoarthritis (OA) is understudied. Methods We used the …

[HTML][HTML] Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and …

M Hiligsmann, C Cooper, N Arden, M Boers… - Seminars in arthritis and …, 2013 - Elsevier
Objectives There is an important need to evaluate therapeutic approaches for osteoarthritis
(OA) in terms of cost-effectiveness as well as efficacy. Methods The ESCEO expert working …

Cost‐effectiveness acceptability curves–facts, fallacies and frequently asked questions

E Fenwick, BJ O'Brien, A Briggs - Health economics, 2004 - Wiley Online Library
Cost‐effectiveness acceptability curves (CEACs) have been widely adopted as a method to
quantify and graphically represent uncertainty in economic evaluation studies of health‐care …

Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from …

AD Sawitzke, H Shi, MF Finco, DD Dunlop… - Annals of the …, 2010 - ard.bmj.com
Background Knee osteoarthritis (OA) is a major cause of pain and functional limitation in
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …

Optimal cost‐effectiveness decisions: the role of the cost‐effectiveness acceptability curve (CEAC), the cost‐effectiveness acceptability frontier (CEAF), and the …

GR Barton, AH Briggs, EAL Fenwick - Value in health, 2008 - Wiley Online Library
Objective: To demonstrate how the optimal decision and level of uncertainty associated with
that decision, can be presented when assessing the cost‐effectiveness of multiple options …

Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes

JA Singh, R Ramachandaran, S Yu… - BMC cardiovascular …, 2017 - Springer
Background Few studies, if any, have examined cardiovascular outcomes in patients with
diabetes and gout. Both diabetes and gout are risk factors for cardiovascular disease. The …

Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump …

S Jarupongprapa, P Ussavasodhi… - Journal of …, 2013 - Springer
Background There are conflicting and inconsistent data regarding the gastrointestinal (GI)
protective effect of cyclooxygenase-2 (COX-2) inhibitors and of non-steroidal anti …

[HTML][HTML] Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?

E Losina, ME Daigle, LG Suter, DJ Hunter… - Osteoarthritis and …, 2013 - Elsevier
OBJECTIVE: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our
goal was to determine efficacy, toxicity, and cost thresholds under which DMOADs would be …